Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+

  Hepatitis C

  Free Subscription


1 Am J Gastroenterol
1 Biochem Biophys Res Commun
1 Clin Res Hepatol Gastroenterol
1 Eur J Gastroenterol Hepatol
2 Gastroenterology
1 Gut
1 J Gen Virol
3 J Hepatol
2 J Viral Hepat
2 PLoS One
1 Scand J Gastroenterol

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Am J Gastroenterol

  1. PEARLMAN B, Perrys M, Hinds A
    Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection.
    Am J Gastroenterol. 2019 May 8. doi: 10.14309/ajg.0000000000000248.
    PubMed     Text format     Abstract available

    Biochem Biophys Res Commun

  2. SHIMIZU Y, Yoneda K, Shirasago Y, Suzuki T, et al
    Human-rat chimeric anti-occludin monoclonal antibodies inhibit hepatitis C virus infection.
    Biochem Biophys Res Commun. 2019 May 9. pii: S0006-291X(19)30887.
    PubMed     Text format     Abstract available

    Clin Res Hepatol Gastroenterol

  3. RAMEZANI A, Baesi K, Banifazl M, Mohraz M, et al
    Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV/HIV patients in iranian population.
    Clin Res Hepatol Gastroenterol. 2019 May 9. pii: S2210-7401(19)30043.
    PubMed     Text format     Abstract available

    Eur J Gastroenterol Hepatol

  4. COSTA M, Rojas Rojas T, Lacoste D, Villes V, et al
    Sleep disturbances in HIV-HCV coinfected patients: indications for clinical management in the HCV cure era (ANRS CO13 HEPAVIH cohort).
    Eur J Gastroenterol Hepatol. 2019 May 14. doi: 10.1097/MEG.0000000000001441.
    PubMed     Text format     Abstract available


  5. WING PAC, Jones M, Cheung M, DaSilva S, et al
    Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir.
    Gastroenterology. 2019 May 9. pii: S0016-5085(19)40865.
    PubMed     Text format     Abstract available

  6. SINGAL AG, Rich NE, Mehta N, Branch A, et al
    Direct-Acting Antiviral Therapy not Associated with Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.
    Gastroenterology. 2019 Jan 17. pii: S0016-5085(19)30057.
    PubMed     Text format     Abstract available


  7. HERZOG K, Bandiera S, Pernot S, Fauvelle C, et al
    Functional microRNA screen uncovers O-linked N-acetylglucosamine transferase as a host factor modulating hepatitis C virus morphogenesis and infectivity.
    Gut. 2019 May 10. pii: gutjnl-2018-317423. doi: 10.1136/gutjnl-2018-317423.
    PubMed     Text format     Abstract available

    J Gen Virol

  8. SHUI J, Liu W, Liang Y, Zhang J, et al
    Infection of human pegivirus 2 (HPgV-2) is associated with hepatitis C virus but not hepatitis B virus infection in people who inject drugs.
    J Gen Virol. 2019 May 15. doi: 10.1099/jgv.0.001266.
    PubMed     Text format     Abstract available

    J Hepatol

  9. ALAVI M, Law MG, Valerio H, Grebely J, et al
    Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    J Hepatol. 2019 May 9. pii: S0168-8278(19)30275.
    PubMed     Text format     Abstract available

  10. JI F, Yeo YH, Wei MT, Ogawa E, et al
    Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
    J Hepatol. 2019 May 13. pii: S0168-8278(19)30279.
    PubMed     Text format     Abstract available

  11. EVON DM, Sarkar S, Amador J, Lok AS, et al
    Patient-reported symptoms during and after direct acting antiviral therapies for chronic hepatitis C: The PROP UP Study.
    J Hepatol. 2019 May 13. pii: S0168-8278(19)30278.
    PubMed     Text format     Abstract available

    J Viral Hepat

  12. MOORE MS, Greene SK, Bocour A, Brown CM, et al
    Comprehensive nationwide chronic hepatitis C surveillance is necessary for accurate state-level prevalence estimates.
    J Viral Hepat. 2019 May 13. doi: 10.1111/jvh.13124.
    PubMed     Text format     Abstract available

  13. MORALES-ARRAEZ D, Alonso-Larruga A, Diaz-Flores F, Garcia Dopico JA, et al
    Predictive factors for not undergoing RNA testing in patients found to have hepatitis C serology and impact of an automatic alert.
    J Viral Hepat. 2019 May 11. doi: 10.1111/jvh.13122.
    PubMed     Text format     Abstract available

    PLoS One

  14. CHEN M, Ma Y, Chen H, Dai J, et al
    Complete genome sequencing and evolutionary analysis of HCV subtype 6xg from IDUs in Yunnan, China.
    PLoS One. 2019;14:e0217010.
    PubMed     Text format     Abstract available

  15. MANGIA A, Piazzolla V, Giannelli A, Visaggi E, et al
    SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.
    PLoS One. 2019;14:e0215783.
    PubMed     Text format     Abstract available

    Scand J Gastroenterol

  16. YUYUN D, Zhihua T, Haijun W, Zhaoping L, et al
    Predictive value of the red blood cell distribution width-to-platelet ratio for hepatic fibrosis.
    Scand J Gastroenterol. 2019;54:81-86.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.